Navigation Links
TNO and Seventh Wave sign letter of intent on joint preclinical pharmaceutical outsourcing services
Date:11/9/2009

Delft, the Netherlands, November 09, 2009 / b3c newswire /- Today, TNO, a Dutch contract research organization, and Seventh Wave, an American organization for contract research and consultancy, announce that the companies have signed a letter of intent with regard to TNOs dynamic in vitro gastrointestinal models TIM. The letter of intent proposes a collaboration in which Seventh Wave will obtain two TIM systems for commercialization in North America. The TIM systems will be used to determine the behavior of oral drug products and drug substances during passage through the gastrointestinal tract.

According to the terms stated in the letter of intent, TNO will supply its proprietary gastrointestinal models to Seventh Wave Laboratories, located in Chesterfield, Missouri. This central U.S. location, coupled with Seventh Waves customer responsiveness, will shorten study turnaround time for customers in North America. The TIM system has been validated for use in preclinical drug development. Both parties expect the TIM systems to be installed and ready for use by customers in the first quarter of 2010. In addition to the collaboration on the current models, the partners envisage joint projects to further validate the TIM system for new applications.

Niek Snoeij, CEO of TNO Quality of life, explains the benefits of the proposed collaboration as follows: The partnership with Seventh Wave allows us to capitalize on the strengths of the TIM system and offer extra capacity, flexibility, and faster turn-around times.

John Sagartz, President and CEO of Seventh Wave, adds: TIM compliments our current preclinical and clinical services. With the TIM system available on site, we have another valuable tool to solve our customers specific needs in formulation development and pharmacokinetics.

TNO gastroIntestinal Model (TIM)
By simulating accurately the human conditions in the gastrointestinal tract, the TIM system gives insight into the release, solubility, and availability for absorption of pharmaceuticals. This state-of-the-art, validated system has a much higher predictive value than regular dissolution tests. The computer-regulated model can simulate various physiologic states and helps scientists determine the bioaccessibility of active compounds and predict resultant blood concentration after single or repeated intake of various dosage forms.


TNO - http://www.tno.nl/pharma
TNO is an innovative, independent research organization. Through its expertise and the research it conducts, TNO contributes to the quality of work and life in the world. TNO supports and stimulates innovations in companies and organizations, thus improving the competitiveness of the economy. TNOs multidisciplinary approach and ability to apply research give it a unique position. More than 4300 professionals work at TNO.

Seventh Wave - www.7thwavelabs.com

Seventh Wave is a consulting and contract research organization providing integrated preclinical ADME/PK, pharmacology, toxicology, pathology, and clinical PK. With a continuous commitment to quality, Seventh Wave operates its consulting and laboratory services as an extension of its clients project teams in the design and timely execution of their preclinical development strategies.


Contact
(in US)
Albert Stevens
Tel: +31 6 15631194

(in Europe)
Heather Wagner
Tel: +31 306944615

Info-pharma@tno.nl
www.tno.nl/pharma


'/>"/>
b3c newswire

Related biology news :

1. AACR to host Seventh Annual International Conference on Frontiers in Cancer Prevention Research
2. Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network
3. Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network
4. FEBS Letters Structured Digital Abstracts experiment
5. BIO-key(R) Issues Open Letter to Shareholders
6. Explorations Group Announces Letter of Intent to Acquire Specialty Lighting Company
7. Explorations Group Announces Letter of Intent to Acquire Specialty Lighting Company
8. Selected personal letters of Max Perutz are released in new book
9. NEWSLETTER: Antibody Fragment Production Breakthrough with 2nd Generation EBA
10. Taser Notices Intent to Serve Subpoena for Information on Old NIJ Tests in Taser v. Stinger
11. Wii bit of fun at Rice University has serious intent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/18/2016)... -- --> --> Competitive ... Unmanned Vehicles, Physical infrastructure and Perimeter Surveillance & Detection Systems ... security market and the continuing migration crisis in the ... has led visiongain to publish this unique report, which ... defence & security companies in the border security market ...
(Date:3/14/2016)... Allemagne, March 14, 2016 ... - --> - Renvoi : image disponible ... --> --> DERMALOG, ... fournit de nouveaux lecteurs d,empreintes digitales pour l,enregistrement ... DERMALOG sera utilisé pour produire des cartes d,identité ...
(Date:3/9/2016)... 2016 This BCC Research report provides an ... RNA Sequencing (RNA Seq) market for the years 2015, ... and reagents, data analysis, and services. Use ... RNA-Sequencing market such as RNA-Sequencing tools and reagents, RNA-Sequencing ... affecting each segment and forecast their market growth, future ...
Breaking Biology News(10 mins):
(Date:5/25/2016)... , ... May 25, 2016 , ... Lajollacooks4u has become ... has consistently been rated one of its top attractions. Fortune 500 companies, such ... participate in a unique and intimate team-building experience. , Each event kicks off with ...
(Date:5/25/2016)... Bethesda, Md. (PRWEB) , ... May 25, 2016 ... ... a request for information (RFI) issued by the Office of the National Coordinator ... the patient experience, and determines if clinically relevant data were available when and ...
(Date:5/25/2016)... ... May 25, 2016 , ... Biohaven Pharmaceutical Holding Company ... granted the company’s orphan drug designation request covering BHV-4157 for the treatment of ... the FDA. , Spinocerebellar ataxia is a rare, debilitating neurodegenerative disorder that ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... identity. The new Media Cybernetics corporate branding reflects a results-driven revitalization for a ... image analysis. The re-branding components include a crisp, refreshed logo and a new ...
Breaking Biology Technology: